Valeo Pharma (TSX:VPH) COGS-to-Revenue : 0.83 (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma COGS-to-Revenue?

Valeo Pharma's Cost of Goods Sold for the three months ended in Jan. 2024 was C$11.28 Mil. Its Revenue for the three months ended in Jan. 2024 was C$13.54 Mil.

Valeo Pharma's COGS to Revenue for the three months ended in Jan. 2024 was 0.83.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Valeo Pharma's Gross Margin % for the three months ended in Jan. 2024 was 16.68%.

Valeo Pharma COGS-to-Revenue Historical Data

The historical data trend for Valeo Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma COGS-to-Revenue Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

COGS-to-Revenue

Get a 7-Day Free Trial

0.79

0.82

0.71

0.77

0.76

Valeo Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
COGS-to-Revenue	Get a 7-Day Free Trial															0.74	0.67	0.70	0.95	0.83

Valeo Pharma COGS-to-Revenue Calculation

Valeo Pharma's COGS to Revenue for the fiscal year that ended in Oct. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	40.833	/	53.91
	=	0.76

Valeo Pharma's COGS to Revenue for the quarter that ended in Jan. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	11.281	/	13.539
	=	0.83

Valeo Pharma (TSX:VPH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Valeo Pharma's Gross Margin % for the three months ended in Jan. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	11.281 / 13.539
	=	16.68 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Valeo Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Valeo Pharma (TSX:VPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

VPHIF:USA

Address

16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website

https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

Executives

Luc Mainville

Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines